Abingdon Health PLC on Monday announced it has signed a partnership agreement with Senzo Health Ltd to provide contract development and manufacturing services to support the firm’s test development.

Senzo is a London-based diagnostics company focused on the rapid diagnostics testing market. Its technology is currently being applied to the development of a Covid-19 antigen assay, a broader respiratory panel, and other infectious disease tests.

Under the newly announced partnership, Abingdon will provide contract development and manufacturing services to Senzo and its partners to enable them to develop and manufacture new rapid tests using Senzo’s amplified lateral flow platform.

Senzo Chief Executive Jeremy Stackawitza said that the partnership will expand the tests being developed and brought to market on its ‘game-changing’ ALF platform.

‘Collaborating with Abingdon creates a valuable synergy for customers looking to bring innovative, high-performance lateral flow products to market, and we’re extremely eager to get to work on the first assays,’ he said.

Shares in Abingdon Health were up 4.6% at 5.49 pence on Monday morning in London.

Copyright 2023 Alliance News Ltd. All Rights Reserved.